A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for further development of this combination in this indication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

NCT01652547

Metastatic Melanoma and Merkel Cell Carcinoma

COMPLETED PHASE1

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

NCT00128102

Mesothelioma Lung Cancer

COMPLETED PHASE3

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

NCT01835184

Recurrent Melanoma Stage IIIA Melanoma Stage IIIB Melanoma +3 more

TERMINATED PHASE1

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

NCT01851408

Melanoma Recurrent Melanoma Stage III Melanoma +1 more

WITHDRAWN PHASE2

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

NCT00565227

Non-Small-Cell Lung Carcinoma Prostate Cancer Bladder Cancer +1 more

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is comprised of 2 sequential parts: Part 1 (Dose Escalation of VS-5584) and Part 2 (Expansion). Up to 56 evaluable subjects (i.e., subjects who complete at least 1 cycle \[21 days\] of therapy) will be enrolled, assuming that:

* Up to 6 dose levels of VS-5584 are studied in Part 1 (Dose Escalation of VS-5584) in combination with a fixed dose of VS-6063 at 400 mg twice daily (BID) with a maximum of 6 subjects enrolled per VS-5584 dose level, for a total of up to 36 subjects (exclusive of replacement subjects).
* Up to an additional 20 evaluable subjects may be enrolled in Part 2, the expansion portion of the study. Subjects will be treated with VS-5584 at the RP2D and schedule determined in the dose escalation portion of the study in combination with a fixed dose of VS-6063.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed Malignant Mesothelioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VS-5584 and VS-6063

Group Type EXPERIMENTAL

VS-5584 and VS-6063

Intervention Type DRUG

Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VS-5584 and VS-6063

Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histopathologically-confirmed diagnosis of malignant mesothelioma (pleural or peritoneal). Must have disease that has relapsed following at least one prior line of chemotherapy.
2. Must have received at least 3 cycles of first-line chemotherapy.
3. Evaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST).
4. Must have archival tumor tissue available for biomarker analysis. A study-specific tumor core biopsy, pleural effusion or ascites sample must be obtained prior to treatment if archival tissue is not available.
5. Performance status according to the Karnofsky Performance Scale ≥70%.
6. Fasting blood glucose of ≤ 140 mg/dL (7.8 mmol/L).
7. Adequate renal function (creatinine ≤ 1.5x upper limit of normal \[ULN\]) and/or glomerular filtration rate (GFR) of ≥50 mL/min.
8. Adequate hepatic function (total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 3x ULN).
9. Adequate bone marrow function (hemoglobin ≥9.0 g/dL; platelets ≥100 x10\^9 cells/L; absolute neutrophil count ≥1.5x10\^9 cells/L) without the use of hematopoietic growth factors.

Exclusion Criteria

1. Have had a previous extra pleural pneumonectomy (EPP).
2. Gastrointestinal condition which could interfere with the swallowing or absorption of study drug.
3. Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases).
4. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.
5. Any evidence of serious active infection.
6. Undergoing active treatment for a secondary malignancy.
7. Cancer-directed therapy (chemotherapy, radiotherapy) within 21 days of the first dose of study drug or 5 half-lives, whichever is shorter.
8. Major surgery within 28 days prior to the first dose of study drug.
9. Acute or chronic pancreatitis.
10. Diabetes mellitus requiring insulin treatment or subjects with a hemoglobin A1C (HbA1C) \>7%.
11. History or evidence of cardiac risk.
12. Known history of malignant hypertension.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No